Combinatorial Treatment of DNA and Chromatin-Modifying Drugs Cause Cell Death in Human and Canine Osteosarcoma Cell Lines

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Thayanithy, Venugopal ^a   Park, ChangWon ^a   Sarver, Aaron L ^b   Kartha, Reena V ^c   Korpela, Derek M ^d   Graef, Ashley J ^d   Steer, Clifford J ^a,d   Modiano, Jaime F ^b,d   Subramanian, Subbaya ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; AZACITIDINE; DNA; HISTONE DEACETYLASE; MICRORNA; MYC PROTEIN; VORINOSTAT; ZEBULARINE;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DEATH; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CYTOTOXICITY; DISEASE COURSE; DNA METHYLATION; DOG; DOWN REGULATION; ENZYME ACTIVITY; EPIGENETICS; GENE CLUSTER; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; NONHUMAN; OSTEOSARCOMA; PATHOLOGY; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; WESTERN BLOTTING;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CHROMATIN; CYTIDINE; DNA; DNA METHYLATION; DOGS; DRUG SCREENING ASSAYS, ANTITUMOR; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; OSTEOSARCOMA;

EID: 84866024491     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043720     Document Type: Article

References (42)

1. Marulanda GA, Henderson ER, Johnson DA, Letson GD, Cheong D, (2008) Orthopedic surgery options for the treatment of primary osteosarcoma. Cancer Control 15: 13-20.
2. Mirabello L, Troisi RJ, Savage SA, (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543.
3. Kansara M, Thomas DM, (2007) Molecular pathogenesis of osteosarcoma. DNA Cell Biol 26: 1-18.
4. Lu XY, Lu Y, Zhao YJ, Jaeweon K, Kang J, et al. (2008) Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res 6: 937-946.
5. Bogenmann E, Moghadam H, DeClerck YA, Mock A, (1987) c-myc amplification and expression in newly established human osteosarcoma cell lines. Cancer Res 47: 3808-3814.
6. Ladanyi M, Park CK, Lewis R, Jhanwar SC, Healey JH, et al. (1993) Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol 2: 163-167.
7. Thayanithy V, Sarver AL, Kartha RV, Li L, Angstadt AY, et al. (2012) Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma. Bone 50: 171-181.
8. Sarver AL, Phalak R, Thayanithy V, Subramanian S, (2010) S-MED: sarcoma microRNA expression database. Lab Invest 90: 753-761.
9. Pallasch CP, Patz M, Park YJ, Hagist S, Eggle D, et al. (2009) miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood 114: 3255-3264.
10. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, et al. (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801.
11. Seitz H, Royo H, Bortolin ML, Lin SP, Ferguson-Smith AC, et al. (2004) A large imprinted microRNA gene cluster at the mouse Dlk1-Gtl2 domain. Genome Res 14: 1741-1748.
12. Agueli C, Cammarata G, Salemi D, Dagnino L, Nicoletti R, et al. (2011) 14q32/miRNA clusters loss of heterozygosity in acute lymphoblastic leukemia is associated with up-regulation of BCL11a. Am J Hematol 85: 575-578.
13. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, et al. (2008) Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 105: 7004-7009.
14. Haller F, von Heydebreck A, Zhang JD, Gunawan B, Langer C, et al. (2010) Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31. J Pathol 220 (1): 71-86.
15. Oberg A, French A, Sarver A, Subramanian S, Morlan B, et al. (2011) MicroRNA expression in colon polyps provides evidence for a multi-hit model of colon cancer. PLoS One 6 (6): e20465.
16. Kircher M, Bock C, Paulsen M, (2008) Structural conservation versus functional divergence of maternally expressed microRNAs in the Dlk1/Gtl2 imprinting region. BMC Genomics 9: 346.
17. Takahashi N, Okamoto A, Kobayashi R, Shirai M, Obata Y, et al. (2009) Deletion of Gtl2, imprinted non-coding RNA, with its differentially methylated region induces lethal parent-origin-dependent defects in mice. Hum Mol Genet 18: 1879-1888.
18. Sarver A, Thayanithy V, Scott MC, Cleaton AM, Hogendoorn PCW, et al. (2011) Expression level of microRNAs at 14q32 locus has prognostic significance in osteosarcoma. Personal communication.
19. Scott MC, Sarver AL, Gavin KJ, Thayanithy V, Getzy DM, et al. (2011) Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. Bone 49: 356-367.
20. Thomas R, Scott A, Langford CF, Fosmire SP, Jubala CM, et al. (2005) Construction of a 2-Mb resolution BAC microarray for CGH analysis of canine tumors. Genome Res 15: 1831-1837.
21. Thomas R, Wang HJ, Tsai PC, Langford CF, Fosmire SP, et al. (2009) Influence of genetic background on tumor karyotypes: evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma. Chromosome Res 17: 365-377.
22. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, et al. (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 89: 1827-1831.
23. Li LC, Dahiya R, (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431.
24. Xiong Z, Laird PW, (1997) COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25: 2532-2534.
25. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, et al. (2006) Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9: 435-443.
26. Schmittgen TD, Livak KJ, (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108.
27. Riccardi C, Nicoletti I, (2006) Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 1: 1458-1461.
28. Fan JB, Yeakley JM, Bibikova M, Chudin E, Wickham E, et al. (2004) A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res 14: 878-885.
29. Pasic I, Shlien A, Durbin AD, Stavropoulos DJ, Baskin B, et al. (2010) Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. Cancer Res 70: 160-171.
30. Moriarty B (2011) An Unbiased Screen for Osteosarcoma Initiation, Progression, and Metastasis Genes. Conference on Genome Engineering, Singapore.
31. Stadtfeld M, Apostolou E, Akutsu H, Fukuda A, Follett P, et al. (2010) Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 465: 175-181.
32. Hagan JP, O'Neill BL, Stewart CL, Kozlov SV, Croce CM, (2009) At least ten genes define the imprinted Dlk1-Dio3 cluster on mouse chromosome 12qF1. PLoS One 4: e4352.
33. Kelly TK, De Carvalho DD, Jones PA, (2010) Epigenetic modifications as therapeutic targets. Nat Biotechnol 28: 1069-1078.
34. Carraway HE, Gore SD, (2007) Addition of histone deacetylase inhibitors in combination therapy. J Clin Oncol 25: 1955-1956.
35. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, et al. (2006) Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191: 465-472.
36. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, et al. (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300.
37. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN, (2005) Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 65: 3815-3822.
38. Munster P, Marchion D, Bicaku E, Schmitt M, Lee JH, et al. (2007) Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25: 1979-1985.
39. Imai T, Adachi S, Nishijo K, Ohgushi M, Okada M, et al. (2003) FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene 22: 9231-9242.
40. Watanabe K, Okamoto K, Yonehara S, (2005) Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 12: 10-18.
41. Wittenburg LA, Bisson L, Rose BJ, Korch C, Thamm DH, (2011) The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother Pharmacol 67: 83-92.
42. Al-Romaih K, Somers GR, Bayani J, Hughes S, Prasad M, et al. (2007) Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: identification of apoptotic genes as targets for demethylation. Cancer Cell Int 7: 14.